Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Rejects Teva's Specifications For Approving Generic Copaxone

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency denies Teva's citizen petition to block approval of pending ANDAs; FDA's Janet Woodcock indicates what tests might be required to show a generic has the same active ingredient as Copaxone.

You may also be interested in...

The Lovenox Benchmark: Copaxone "Far More Complex," Teva Argues In Anti-Generic Petition

Teva is using FDA’s rationale for approving generic Lovenox to argue against the approval of ANDAs for generic versions of its multiple sclerosis drug Copaxone (glatiramer).

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts